New study checks if a common HIV pill works after prevention shot failure
NCT ID NCT06485154
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests a three-drug HIV pill (TLD) as first treatment in 100 people who recently received cabotegravir long-acting PrEP shots but still got HIV. Researchers will check if the pill can suppress the virus to undetectable levels by 6 months. Participants are followed for a year to also track drug resistance patterns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Africa Health Research Institute (AHRI)
RECRUITINGDurban, KwaZulu-Natal, 3935, South Africa
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Desmond Tutu Health Foundation
RECRUITINGCape Town, Western Cape, 7925, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Ezintsha, a division of Wits Health Consortium
RECRUITINGJohannesburg, Gauteng, 2193, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir, Lamivudine, and Dolutegravir (a 3-in-1 pill)
What this could lead to
If it works, this could confirm that a standard HIV pill is effective for people who got HIV despite using long-acting injectable PrEP.
What could go wrong
This is a small, single-arm study with no comparison group, so results may not apply broadly. Drug resistance from prior PrEP could reduce effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.